Determination of moxifloxacin in human plasma, plasma ultrafiltrate, and cerebrospinal fluid by a rapid and simple liquid chromatography-tandem mass spectrometry method

Journal of Analytical Toxicology

Volumn 34, Issue 3, 2010, Pages 135-141

  Pranger, Arianna D ^a   Alffenaar, Jan Willem C ^a   Wessels, A Mireille A ^a   Greijdanus, Ben ^a   Uges, Donald R A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; CIANOPRAMINE; DRUG DERIVATIVE; HETEROCYCLIC COMPOUND; IMIPRAMINE; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ACCURACY; ARTICLE; CALIBRATION; CEREBROSPINAL FLUID; CONCENTRATION (PARAMETERS); DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG MONITORING; DRUG STABILITY; DRUG STRUCTURE; IONIZATION; LINEAR REGRESSION ANALYSIS; LIQUID CHROMATOGRAPHY; PROTEIN BINDING; QUALITY CONTROL; SENSITIVITY ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRAFILTRATION; AREA UNDER THE CURVE; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METHODOLOGY; REPRODUCIBILITY; TUBERCULOUS MENINGITIS;

MYCOBACTERIUM TUBERCULOSIS;

ANTITUBERCULAR AGENTS; AREA UNDER CURVE; AZA COMPOUNDS; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG MONITORING; HUMANS; IMIPRAMINE; QUINOLINES; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; TUBERCULOSIS, MENINGEAL; ULTRAFILTRATION;

EID: 77957044310     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/34.3.135     Document Type: Article

References (31)

1. A.S. Ginsburg, J.H. Grosset, and W.R. Bishai. Fluoroquinolones, tuberculosis, and resistance. Lancet Infect. Dis. 3(7): 432-442 (2003).
2. J.C. Rodriguez, M. Ruiz, M. Lopez, and G. Royo. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 20(6): 464-467 (2002).
3. E.L. Nuermberger,T.Yoshimatsu, S.Tyagi, R.J. O'Brien, A.N.Vernon, R.E. Chaisson, W.R. Bishai, and J.H. Grosset. Moxifloxacincontaining regimen greatly reduces time to culture conversion in murine tuberculosis. Am. J. Respir. Crit. Care Med. 169(3): 421- 426 (2004).
4. H.M. Blumberg, W.J. Burman, R.E. Chaisson, C.L. Daley, S.C. Etkind, L.N. Friedman,P.Fujiwara,M.Grzemska, P.C. Hopewell, M.D. Iseman, R.M. Jasmer,V. Koppaka, R.I. Menzies, R.J. O'Brien, R.R. Reves, L.B. Reichman, P.M. Simone, J.R. Starke, and A.A. Vernon. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am. J. Respir. Crit. Care Med. 167(4): 603- 662 (2003).
5. R. Shi, N. Itagaki, and I. Sugawara. Overview of anti-tuberculosis (TB) drugs and their resistance mechanisms. Mini Rev. Med. Chem. 7(11): 1177-1185 (2007).
6. J.W. Alffenaar, P.M. de Vries, G.J. Luijckx, D. van Soolingen, T.S. van der Werf, and R. van Altena. Plasma and cerebrospinal fluid pharmacokinetics of moxifloxacin in a patient with tuberculous meningitis. Antimicrob. Agents Chemother. 52(6): 2293- 2295 (2008).
7. V. Rodriguez-Cerrato, C.C. McCoig, I.C. Michelow, F. Ghaffar, H.S. Jafri, R.D. Hardy, C. Patel, K. Olsen, and G.H. McCracken, Jr. Pharmacodynamics and bactericidal activity of moxifloxacin in experimental Escherichia coli meningitis. Antimicrob. Agents Chemother. 45(11): 3092-3097 (2001).
8. H. Schmidt, A. Dalhoff, K. Stuertz, F. Trostdorf, V. Chen, O. Schneider, C. Kohlsdorfer, W. Bruck, and R. Nau. Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob. Agents Chemother. 42(6): 1397-1407 (1998).
9. C. Ostergaard, T.K. Sorensen, J.D. Knudsen, and N. Frimodt-Moller. Evaluation of moxifloxacin, a new 8-methoxyquinolone, for treatment of meningitis caused by a penicillin-resistant pneumococcus in rabbits. Antimicrob. Agents Chemother. 42(7): 1706-1712 (1998).
10. R.K. Shandil, R. Jayaram, P. Kaur, S. Gaonkar, B.L. Suresh, B.N. Mahesh, R. Jayashree,V. Nandi, S. Bharath, andV. Balasub-ramanian. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob. Agents Chemother. 51(2): 576-582 (2007).
11. H.M.J. Nijland, R. Ruslami, A.J. Suroto, D.M. Burger, B. Alisjah-bana, R. van Crevel, and R.E. Aarnoutse. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin. Infect. Diseases 45(8): 1001-1007 (2007).
12. M. Weiner, W. Burman, C.C. Luo, C.A. Peloquin, M. Engle, S. Goldberg, V. Agarwal, and A. Vernon. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob. Agents Chemother. 51(8): 2861-2866 (2007).
13. Y. Dong, C. Xu, X. Zhao, J. Domagala, and K. Drlica. Fluoro-quinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob. Agents Chemother. 42(11): 2978-2984 (1998).
14. K. Drlica and M. Malik. Fluoroquinolones: action and resistance. Curr. Top Med. Chem. 3(3): 249-282 (2003).
15. K.M. Kam, C.W. Yip, T.L. Cheung, H.S. Tang, O.C. Leung, and M.Y. Chan. Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: correlation with ofloxacin susceptibility. Microb. Drug Resist. 12(1): 7-11 (2006).
16. T. Gumbo, A. Louie, M.R. Deziel, L.M. Parsons, M. Salfinger, and G.L. Drusano. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J. Infect Dis. 190(9): 1642-1651 (2004).
17. G.J. Noel, J. Natarajan, S. Chien, T.L. Hunt, D.B. Goodman, and R. Abels. Effects of three fluoroquinolones on QT interval in healthy adults after single doses. Clin. Pharmacol. Ther. 73(4): 292-303 (2003).
18. M. Zeitlinger, R. Sauermann, M. Fille, J. Hausdorfer, I. Leitner, and M. Muller. Plasma protein binding of fluoroquinolones affects antimicrobial activity. J. Antimicrob. Chemother. 61(3): 561-567 (2008).
19. A. Laban-Djurdjevic, M. Jelikic-Stankov, and P. Djurdjevic. Optimization and validation of the direct HPLC method for the determination of moxifloxacin in plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 844(1): 104-111 (2006).
20. S. Schulte, T. Ackermann, N. Bertram, T. Sauerbruch, and W.D. Paar. Determination of the newer quinolones levofloxacin and moxifloxacin in plasma by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. Sci. 44(4): 205-208 (2006).
21. N. Srinivas, L. Narasu, B.P. Shankar, and R. Mullangi. Development and validation of a HPLC method for simultaneous quantitation of gatifloxacin, sparfloxacin and moxifloxacin using lev-ofloxacin as internal standard in human plasma: application to a clinical pharmacokinetic study. Biomed. Chromatogr. 22(11): 1288-1295 (2008).
22. K. Kanellakopoulou, A. Pagoulatou, K. Stroumpoulis, M. Vafi-adou, H. Kranidioti, H. Giamarellou, and E.J. Giamarellos-Bour-boulis. Pharmacokinetics of moxifloxacin in non-inflamed cerebrospinal fluid of humans: implication for a bactericidal effect. J. Antimicrob. Chemother. 61(6): 1328-1331 (2008).
23. K. Vishwanathan, M.G. Bartlett, and J.T. Stewart. Determination of moxifloxacin in human plasma by liquid chromatography electrospray ionization tandem mass spectrometry. J. Pharm. Biomed. Anal. 30(4): 961-968 (2002).
24. U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry. Bioanalytical Method Validation, 2001.
25. Bayer HealthCare. Moxifloxacin HCl Certificate of Analysis, 1999.
26. A. Clouser-Roche, K. Johnson, D. Fast, and D. Tang. Beyond pass/fail: a procedure for evaluating the effect of carryover in bioanalytical LC-MS-MS methods. J. Pharm. Biomed. Anal. 47(1): 146-155 (2008).
27. J.W. Dolan. Autosampler carryover. Why is the blank never clean? LCGC Europe 19(10): 522-529 (2006).
28. N. Weng and T.D.J. Halls. Systematic troubleshooting for LC- MS-MS part 2: Large-scale LC-MS-MS and Automation. Bio-Pharm. 15(1): 22-26 (2002)
29. Millipore Corporation. Centrifree Ultrafiltration Devices For In Vitro Use, 2006.
30. W. MacMahon, J.Thompson, W. Bowers, and D. Sgoutas. A simplified ultrafiltration method for determination of serum free cortisol. Clin. Chim. Acta 131(3): 171-184 (1983).
31. M.B. Conde, A. Efron, C. Loredo, G.R. De Souza, N.P. Graca, M.C. Cezar, M. Ram, M.A. Chaudhary, W.R. Bishai, A.L. Kritski, and R.E. Chaisson. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 373(9670): 1183-1189 (2009).